493 related articles for article (PubMed ID: 3486041)
1. Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma.
Kalland T
Cancer Res; 1986 Jun; 46(6):3018-22. PubMed ID: 3486041
[TBL] [Abstract][Full Text] [Related]
2. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases.
Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534
[TBL] [Abstract][Full Text] [Related]
3. Growth inhibition of established B16-F10 lung metastases by sequential aerosol delivery of p53 gene and 9-nitrocamptothecin.
Gautam A; Waldrep JC; Densmore CL; Koshkina N; Melton S; Roberts L; Gilbert B; Knight V
Gene Ther; 2002 Mar; 9(5):353-7. PubMed ID: 11938455
[TBL] [Abstract][Full Text] [Related]
4. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
5. Immune regulation of metastasis from in vivo derived syngeneic murine melanoma.
Harning R; Koo GC; Szalay J
Reg Immunol; 1990; 3(2):97-102. PubMed ID: 1965137
[TBL] [Abstract][Full Text] [Related]
6. Augmentation of the antimetastatic effect of anticoagulant drugs by immunostimulation in mice.
Gorelik E
Cancer Res; 1987 Feb; 47(3):809-15. PubMed ID: 3802083
[TBL] [Abstract][Full Text] [Related]
7. Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator.
Kalland T; Alm G; Stålhandshe T
J Immunol; 1985 Jun; 134(6):3956-61. PubMed ID: 2580900
[TBL] [Abstract][Full Text] [Related]
8. Cure of B16F10 melanoma lung metastasis in mice by chronic indomethacin therapy combined with repeated rounds of interleukin 2: characteristics of killer cells generated in situ.
Lala PK; Parhar RS
Cancer Res; 1988 Mar; 48(5):1072-9. PubMed ID: 3124954
[TBL] [Abstract][Full Text] [Related]
9. Regulation of the metastasis of murine ocular melanoma by natural killer cells.
Harning R; Koo GC; Szalay J
Invest Ophthalmol Vis Sci; 1989 Sep; 30(9):1909-15. PubMed ID: 2777511
[TBL] [Abstract][Full Text] [Related]
10. Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon.
Abdel-Wahab Z; Dar M; Osanto S; Fong T; Vervaert CE; Hester D; Jolly D; Seigler HF
Cancer Gene Ther; 1997; 4(1):33-41. PubMed ID: 9012449
[TBL] [Abstract][Full Text] [Related]
11. Enhanced suppression of pulmonary metastasis of malignant melanoma cells by combined administration of alpha-galactosylceramide and interleukin-18.
Nishio S; Yamada N; Ohyama H; Yamanegi K; Nakasho K; Hata M; Nakamura Y; Fukunaga S; Futani H; Yoshiya S; Ueda H; Taniguchi M; Okamura H; Terada N
Cancer Sci; 2008 Jan; 99(1):113-20. PubMed ID: 17949451
[TBL] [Abstract][Full Text] [Related]
12. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
13. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
14. Extraction of immunogenic and suppressogenic antigens from variants of B16 melanoma exhibiting low or high metastatic potentials.
LeGrue SJ; Hearn DR
Cancer Res; 1983 Nov; 43(11):5106-11. PubMed ID: 6616449
[TBL] [Abstract][Full Text] [Related]
15. Augmentation of murine natural killer cell activity by swainsonine, a new antimetastatic immunomodulator.
Humphries MJ; Matsumoto K; White SL; Molyneux RJ; Olden K
Cancer Res; 1988 Mar; 48(6):1410-5. PubMed ID: 3125963
[TBL] [Abstract][Full Text] [Related]
16. Age-dependent experimental tumor dissemination of murine melanoma B16.
Baumgart J; Zippel D
Arch Immunol Ther Exp (Warsz); 1991; 39(5-6):489-94. PubMed ID: 1841547
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells.
Sabel MS; Arora A; Su G; Mathiowitz E; Reineke JJ; Chang AE
Surgery; 2007 Nov; 142(5):749-60. PubMed ID: 17981196
[TBL] [Abstract][Full Text] [Related]
18. Effect of antiplatelet antibody on the development of pulmonary metastases following injection of CT26 colon adenocarcinoma, Lewis lung carcinoma, and B16 amelanotic melanoma tumor cells into mice.
Pearlstein E; Ambrogio C; Karpatkin S
Cancer Res; 1984 Sep; 44(9):3884-7. PubMed ID: 6744304
[TBL] [Abstract][Full Text] [Related]
19. Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases.
Eisenthal A; Cameron RB; Uppenkamp I; Rosenberg SA
Cancer Res; 1988 Dec; 48(24 Pt 1):7140-5. PubMed ID: 3263900
[TBL] [Abstract][Full Text] [Related]
20. Characterization in vivo and in vitro of tumor cells selected for resistance to syngeneic lymphocyte-mediated cytotoxicity.
Fidler IJ; Gersten DM; Budmen MB
Cancer Res; 1976 Sep; 36(9 pt.1):3160-5. PubMed ID: 975082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
